A KDIGO review highlights that valvular heart disease in chronic kidney disease patients has distinct pathophysiology and higher risks, summarizing knowledge gaps and research priorities.
This KDIGO review highlights the unique pathophysiology and elevated risks of valvular heart disease in patients with chronic kidney disease, emphasizing the need for tailored research and management strategies.
Chronic kidney disease (CKD) is a major risk factor for valvular heart disease (VHD). Mitral annular and aortic valve calcifications are highly prevalent in CKD patients and commonly lead to valvular stenosis and regurgitation, as well as complications including conduction system abnormalities and endocarditis. VHD, especially mitral regurgitation and aortic stenosis, is associated with significantly reduced survival among CKD patients. Knowledge related to VHD in the general population is not always applicable to CKD patients because the pathophysiology may be different, and CKD patients have a high prevalence of comorbid conditions and elevated risk for periprocedural complications and mortality. This Kidney Disease: Improving Global Outcomes (KDIGO) review of CKD and VHD seeks to improve understanding of the epidemiology, pathophysiology, diagnosis, and treatment of VHD in CKD by summarizing knowledge gaps, areas of controversy, and priorities for research.
Marwick et al. (Thu,) conducted a review in Chronic kidney disease and valvular heart disease. A KDIGO review highlights that valvular heart disease in chronic kidney disease patients has distinct pathophysiology and higher risks, summarizing knowledge gaps and research priorities.